The agency has granted an accelerated approval for trastuzumab deruxtecan (Enhertu) to be used in patients with metastatic non–small cell lung cancer whose tumors have HER2 mutations.
FDA Approvals
FDA Approves Enhertu (Trastuzumab Deruxtecan) for HER2 Lung Cancer
